x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:05:00

Hepatic Encephalopathy: More Common Than You Think

ReachMD CME ·

2025/12/11

CME credits: 1.00Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and

en

00:04:45

Current Treatment of Hepatic Encephalopathy: Is It...

ReachMD CME ·

2025/12/11

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Current-Treatment-of-Hepatic-Encephalopathy-Is-It-Meeting-Our-Patients-Needs/39793/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection,

en

00:05:15

Optimizing Care of the Hospitalized Patient With...

ReachMD CME ·

2025/12/11

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Optimizing-Care-of-the-Hospitalized-Patient-With-Overt-Hepatic-Encephalopathy/39792/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection,

en

00:22:30

Advances in Treatment of Hypoparathyroidism:...

ReachMD CME ·

2025/12/10

CME credits: 0.50 Valid until: 10-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-treatment-of-hypoparathyroidism-importance-of-genetic-testing-for-autosomal-dominant-hypocalcemia-type-1/36097/ This CME activity focuses on enhancing clinician recognition and management of autosomal dominant hypocalcemia type 1 (ADH1). Learners will explore the pathophysiology and clinical manifestations of ADH1, understand barriers to timely diagnosis, gain practical strategies

en

00:31:00

Taking Action Against RSV: No Child Unprotected

ReachMD CME ·

2025/12/04

CME credits: 0.50 Valid until: 04-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/taking-action-against-rsv-no-child-unprotected/39307/ This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved

en

00:12:45

Early Action in Obesity: Transforming Practice,...

ReachMD CME ·

2025/12/03

CME credits: 0.25 Valid until: 03-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/early-action-in-obesity-transforming-practice-improving-outcomes/36273/ Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The

en

00:14:30

Rethinking Schizophrenia Treatment Through Muscarinic...

ReachMD CME ·

2025/12/02

CME credits: 0.25 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/ In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional

en

00:05:00

Future mCRC Directions: Enhancing Anti-EGFR Therapy...

ReachMD CME ·

2025/12/02

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-mcrc-directions-enhancing-anti-egfr-therapy-with-novel-combination-strategies/48870/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

en

00:14:30

A Clear Horizon in Plaque Psoriasis: An Update on...

ReachMD CME ·

2025/11/26

CME credits: 0.25Valid until: 26-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/ Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and

en

00:14:00

IgAN Management Into Practice: Evolving Guidelines &...

ReachMD CME ·

2025/11/19

CME credits: 0.25 Valid until: 19-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/ Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses

en

00:10:30

Engaging Your Patient: Shared Decision-Making in HF...

ReachMD CME ·

2025/11/18

CME credits: 0.25 Valid until: 18-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/ Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and

en

00:05:30

Navigating the Therapeutic Landscape of...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific

en

00:29:30

The Fifth Pillar? Closing the Gap in HFrEF

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-fifth-pillar-closing-the-gap-in-hfref/37615/ For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despite the use of quadruple pharmacologic guideline-directed medical therapy (GDMT) and medical

en

00:07:00

Looking Ahead: Integrating CDH6-Targeted Therapies...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/looking-ahead-integrating-cdh6-targeted-therapies-into-ovarian-cancer-treatment-paradigms/37866/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the

en

00:06:15

MOA: CDH6-Targeted Antibody-Drug Conjugates

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver

en

00:07:15

Safety and Tolerability of CDH6-Directed...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific

en

00:06:45

Clinical Evidence: Insights From Early Trials of...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific

en

00:16:30

Advancing gMG Clinical Decisions: Diagnosing Early,...

ReachMD CME ·

2025/11/13

CME credits: 0.25 Valid until: 15-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-gmg-clinical-decisions-diagnosing-early-treating-smarter-and-caring-holistically-a-case-based-treatment-approach/36276/ This case-based discussion follows Maria, a 38-year-old teacher presenting with fluctuating ptosis, diplopia, and fatigue—classic but easily overlooked signs of generalized myasthenia gravis (gMG). Drs. Goyal and Edmundson review diagnostic strategies for gMG,

en

00:16:15

Treating MASH With Compensated Cirrhosis: A Serious...

ReachMD CME ·

2025/11/11

CME credits: 0.25 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/treating-mash-with-compensated-cirrhosis-a-serious-unmet-need/37646/ Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify

en

00:42:00

Advancing Clinical Expertise in CELMoDs: Transforming...

ReachMD CME ·

2025/11/10

CME credits: 1.00 Valid until: 10-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-clinical-expertise-in-celmods-transforming-multiple-myeloma-treatment/35631/ This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential to bridge

en

387 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事